STAAR Surgical Reports Third Quarter 2023 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended September 29, 2023. Third Quarter 2023 Overview Net Sales of $80.3 Million Up 6% Y/Y includes a $0.8 Million sales reduction related to Other Products ICL Sales of $81.1 Million Up 13% Y/Y ICL Units Up 14% Y/Y Gross Ma